Humana (HUM) Financials

$226.49 +1.56 (+0.69%)

Closing price 05/27/2025 03:59 PM Eastern

Extended Trading

$227.35 +0.86 (+0.38%)

As of 06:03 AM Eastern

Annual Income Statements for Humana

This table shows Humana's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	1,207	2,489	2,806	2,933	3,367	2,707	1,683	2,448	614	1,276
Consolidated Net Income / (Loss)	1,214	2,484	2,802	2,934	3,367	2,707	1,683	2,448	614	1,276
Net Income / (Loss) Continuing Operations	1,214	2,484	2,802	2,934	3,367	2,707	1,683	2,448	614	1,276
Total Pre-Tax Income	1,721	3,383	3,568	3,354	4,600	3,456	2,063	4,020	1,552	2,431
Total Operating Income	2,562	4,013	3,800	3,148	4,986	3,192	3,100	4,262	1,741	2,347
Total Gross Profit	17,097	17,980	17,180	13,865	15,527	11,031	11,030	10,271	9,372	10,020
Total Revenue	117,761	106,374	92,870	83,064	77,155	64,888	56,912	53,767	54,379	54,289
Operating Revenue	116,535	105,305	92,488	82,877	76,001	64,387	56,912	53,767	54,379	54,289
Other Revenue	1,226	1,069	382	187	1,154	-	-	-	-	-
Total Cost of Revenue	100,664	88,394	75,690	69,199	61,628	53,857	45,882	43,496	45,007	44,269
Operating Cost of Revenue	100,664	88,394	75,690	69,199	61,628	53,857	45,882	43,496	45,007	44,269
Total Operating Expenses	14,535	13,967	13,380	10,717	10,541	7,839	7,930	6,009	7,631	7,673
Selling, General & Admin Expense	13,696	13,188	12,671	10,121	10,052	7,381	7,525	6,567	7,173	7,295
Depreciation Expense	839	779	709	596	489	458	405	378	354	355
Total Other Income / (Expense), net	-841	-630	-232	206	-386	264	-1,037	-242	-189	84
Interest Expense	660	493	401	326	283	242	218	242	189	186
Other Income / (Expense), net	-181	-137	169	532	-103	506	-819	0.00	0.00	270
Income Tax Expense	413	836	762	485	1,307	763	391	1,572	938	1,155
Other Gains / (Losses), net	-94	-63	-4.00	65	74	14	11	0.00	-	-
Net Income / (Loss) Attributable to Noncontrolling Interest	7.00	-5.00	-4.00	1.00	0.00	0.00	-	-	-	-
Basic Earnings per Share	$10.01	$20.09	$22.20	$22.79	$25.47	$20.20	$12.24	$16.94	$4.11	$8.54
Weighted Average Basic Shares Outstanding	120.64M	120.65M	124.97M	126.63M	128.86M	132.11M	137.49M	144.49M	149.38M	149.46M
Diluted Earnings per Share	$9.98	$20.00	$22.08	$22.67	$25.31	$20.10	$12.16	$16.81	$4.07	$8.44
Weighted Average Diluted Shares Outstanding	120.64M	120.65M	124.97M	126.63M	128.86M	132.11M	137.49M	144.49M	149.38M	149.46M
Weighted Average Basic & Diluted Shares Outstanding	120.64M	120.65M	124.97M	126.63M	128.86M	132.11M	137.49M	144.49M	149.38M	149.46M
Cash Dividends to Common per Share	$3.54	$3.44	$3.06	$2.73	$2.43	$2.15	$1.90	$1.49	$1.16	$1.14

This table shows Humana's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	1,244	-693	480	679	741	-541	832	959	1,239	-15	1,195
Consolidated Net Income / (Loss)	1,242	-683	480	678	739	-540	830	956	1,238	-18	1,193
Net Income / (Loss) Continuing Operations	1,242	-683	480	678	739	-540	830	956	1,238	-18	1,193
Total Pre-Tax Income	1,691	-862	651	918	1,014	-591	1,098	1,262	1,614	-71	1,297
Total Operating Income	2,014	-543	728	1,141	1,236	-348	1,206	1,436	1,719	124	1,172
Total Gross Profit	5,577	3,832	4,277	4,501	4,487	3,680	4,678	4,738	4,884	3,857	4,415
Total Revenue	32,112	29,213	29,397	29,540	29,611	26,462	26,423	26,747	26,742	22,439	22,799
Operating Revenue	31,848	28,916	29,054	29,242	29,323	26,168	26,115	26,473	26,549	22,279	22,627
Other Revenue	264	297	343	298	288	294	308	274	193	-	172
Total Cost of Revenue	26,535	25,381	25,120	25,039	25,124	22,782	21,745	22,009	21,858	18,582	18,384
Operating Cost of Revenue	26,535	25,381	25,120	25,039	25,124	22,782	21,745	22,009	21,858	18,582	18,384
Total Operating Expenses	3,563	4,375	3,549	3,360	3,251	4,028	3,472	3,302	3,165	3,733	3,243
Selling, General & Admin Expense	3,380	4,167	3,339	3,148	3,042	3,827	3,271	3,111	2,979	3,551	3,061
Depreciation Expense	183	208	210	212	209	201	201	191	186	182	182
Total Other Income / (Expense), net	-323	-319	-77	-223	-222	-243	-108	-174	-105	-195	125
Interest Expense	160	164	169	168	159	146	114	120	113	108	102
Other Income / (Expense), net	-163	-155	92	-55	-63	-97	6.00	-54	8.00	-87	227
Income Tax Expense	406	-216	155	223	251	-75	256	296	359	-58	107
Other Gains / (Losses), net	-43	-37	-16	-17	-24	-24	-12	-10	-17	-5.00	3.00
Net Income / (Loss) Attributable to Noncontrolling Interest	-2.00	10	0.00	-1.00	-2.00	1.00	-2.00	-3.00	-1.00	-3.00	-2.00
Basic Earnings per Share	$10.31	($5.74)	$3.99	$5.63	$6.13	($4.26)	$6.74	$7.70	$9.91	($0.07)	$9.45
Weighted Average Basic Shares Outstanding	120.69M	120.64M	120.41M	120.40M	120.50M	120.65M	123.11M	123.91M	124.94M	124.97M	126.60M
Diluted Earnings per Share	$10.30	($5.73)	$3.98	$5.62	$6.11	($4.24)	$6.71	$7.66	$9.87	($0.08)	$9.39
Weighted Average Diluted Shares Outstanding	120.69M	120.64M	120.41M	120.40M	120.50M	120.65M	123.11M	123.91M	124.94M	124.97M	126.60M
Weighted Average Basic & Diluted Shares Outstanding	120.69M	120.64M	120.41M	120.40M	120.50M	120.65M	123.11M	123.91M	124.94M	124.97M	126.60M

This table details how cash moves in and out of Humana's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	-2,473	-367	1,667	-1,279	619	1,711	-1,699	165	1,306	636
Net Cash From Operating Activities	2,966	3,981	4,587	2,262	5,639	5,284	2,173	4,051	1,936	868
Net Cash From Continuing Operating Activities	2,966	3,981	4,587	2,262	5,639	5,284	2,173	4,051	1,936	868
Net Income / (Loss) Continuing Operations	1,214	2,484	2,802	2,934	3,367	2,707	1,683	2,448	614	1,276
Consolidated Net Income / (Loss)	1,214	2,484	2,802	2,934	3,367	2,707	1,683	2,448	614	1,276
Depreciation Expense	908	850	749	640	528	505	444	410	388	354
Amortization Expense	60	67	96	73	88	70	90	75	77	93
Non-Cash Adjustments To Reconcile Net Income	714	553	436	-884	-731	51	822	241	58	-246
Changes in Operating Assets and Liabilities, net	70	27	504	-501	2,387	1,951	-866	877	799	-609
Net Cash From Investing Activities	-2,952	-3,492	-1,006	-6,556	-3,065	-1,278	-3,087	-2,941	-1,362	320
Net Cash From Continuing Investing Activities	-2,952	-3,492	-1,006	-6,556	-3,065	-1,278	-3,087	-2,941	-1,362	320
Purchase of Property, Plant & Equipment	-575	-1,004	-1,137	-1,342	-964	-736	-612	-524	-527	-523
Acquisitions	-89	-233	-337	-4,187	-709	0.00	-2,254	-31	-7.00	-38
Purchase of Investments	-8,603	-7,552	-6,049	-7,197	-9,125	-6,361	-4,687	-6,265	-6,566	-6,739
Sale of Property, Plant & Equipment	7.00	210	17	26	-	-	-	-	-	1.00
Divestitures	0.00	0.00	2,701	0.00	0.00	-	-	0.00	0.00	1,061
Sale and/or Maturity of Investments	6,358	5,087	3,799	6,144	7,733	5,819	4,466	3,879	5,738	6,558
Other Investing Activities, net	-50	0.00	0.00	-	-	-	-	-	-	-
Net Cash From Financing Activities	-2,487	-856	-1,914	3,015	-1,955	-2,295	-785	-945	732	-552
Net Cash From Continuing Financing Activities	-2,487	-856	-1,914	3,015	-1,955	-2,295	-785	-945	732	-552
Repayment of Debt	-2,129	-2,379	-3,373	-1,736	-1,056	-1,410	-350	-953	-2.00	298
Repurchase of Common Equity	-817	-1,573	-2,096	-79	-1,820	-1,070	-1,090	-3,365	-104	-385
Payment of Dividends	-431	-431	-392	-354	-323	-291	-265	-220	-177	-172
Issuance of Debt	2,232	2,644	1,982	5,484	2,088	987	1,485	1,779	0.00	0.00
Other Financing Activities, net	-1,342	883	1,965	-300	-844	-511	-565	1,814	1,015	-293
Cash Interest Paid	584	394	354	285	258	212	195	216	185	187
Cash Income Taxes Paid	570	997	758	227	1,132	518	631	1,498	916	1,179

This table details how cash moves in and out of Humana's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	2,029	-2,895	-385	-409	1,216	-10,454	-1,066	2,479	8,674	-8,497	8,338
Net Cash From Operating Activities	331	-528	1,858	1,213	423	-7,134	1,252	3,176	6,687	-5,127	8,453
Net Cash From Continuing Operating Activities	331	-528	1,858	1,213	423	-7,134	1,252	3,176	6,687	-5,127	8,453
Net Income / (Loss) Continuing Operations	1,242	-683	480	678	739	-540	830	956	1,238	-18	1,193
Consolidated Net Income / (Loss)	1,242	-683	480	678	739	-540	830	956	1,238	-18	1,193
Depreciation Expense	200	226	228	228	226	222	218	210	200	194	186
Amortization Expense	15	14	15	15	16	16	17	16	18	23	28
Non-Cash Adjustments To Reconcile Net Income	99	385	101	127	101	292	-6,992	7,138	115	224	-170
Changes in Operating Assets and Liabilities, net	-1,225	-470	1,034	165	-659	-7,124	7,179	-5,144	5,116	-5,550	7,216
Net Cash From Investing Activities	314	-63	-1,473	-1,002	-414	-882	-585	-733	-1,292	-1,012	1,676
Net Cash From Continuing Investing Activities	314	-63	-1,473	-1,002	-414	-882	-585	-733	-1,292	-1,012	1,676
Purchase of Property, Plant & Equipment	-95	-154	-130	-114	-177	-283	-234	-264	-223	-275	-288
Acquisitions	0.00	-52	-20	-3.00	-14	-10	-34	-116	-73	-44	-126
Purchase of Investments	-1,002	-2,200	-3,441	-1,703	-1,259	-4,186	-629	-1,424	-1,313	-1,309	-1,501
Sale and/or Maturity of Investments	1,411	2,386	2,118	818	1,036	3,387	312	1,071	317	606	883
Net Cash From Financing Activities	1,384	-2,304	-770	-620	1,207	-2,438	-1,733	36	3,279	-2,358	-1,791
Net Cash From Continuing Financing Activities	1,384	-2,304	-770	-620	1,207	-2,438	-1,733	36	3,279	-2,358	-1,791
Repayment of Debt	-19	-1,440	261	-272	-678	-1,639	-5.00	112	-847	-698	-2,244
Repurchase of Common Equity	-9.00	-49	-2.00	-49	-717	-571	-379	-529	-94	-1,064	-4.00
Payment of Dividends	-108	-108	-107	-107	-109	-111	-109	-111	-100	-101	-100
Issuance of Debt	1,481	-	-	-	2,232	1,429	-	-	1,215	1,238	-
Other Financing Activities, net	39	-707	-922	-192	479	-1,546	-1,240	564	3,105	-1,733	557
Cash Interest Paid	143	168	166	92	158	77	142	78	97	98	85
Cash Income Taxes Paid	-12	-	208	361	1.00	40	276	675	6.00	7.00	378

This table presents Humana's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Total Assets	46,479	47,065	43,055	44,358	34,969	29,074	25,413	27,178	25,396	24,678
Total Current Assets	29,815	29,986	26,183	24,893	23,641	19,888	16,948	17,402	16,190	15,711
Cash & Equivalents	2,221	4,694	5,061	3,394	4,673	4,054	2,343	4,042	3,877	2,571
Short-Term Investments	18,214	16,626	13,881	13,192	12,554	10,972	10,026	9,557	7,595	7,267
Accounts Receivable	2,704	2,035	1,674	1,814	1,138	1,056	1,015	854	1,280	1,161
Other Current Assets	6,676	6,631	5,567	6,493	5,276	3,806	3,564	2,949	3,438	4,712
Plant, Property, & Equipment, net	2,532	3,030	3,221	3,073	2,371	1,955	1,735	1,584	1,505	1,384
Total Noncurrent Assets	14,132	14,049	13,651	16,392	8,957	7,231	6,730	8,192	7,701	7,583
Long-Term Investments	1,118	1,122	1,129	921	2,382	1,469	1,458	2,745	2,203	1,843
Goodwill	9,631	9,550	9,142	11,092	4,447	3,928	3,897	3,281	3,272	3,265
Other Noncurrent Operating Assets	3,383	3,377	3,380	4,379	2,128	1,834	1,375	2,166	2,226	2,475
Total Liabilities & Shareholders' Equity	46,479	47,065	43,055	44,358	34,969	29,074	25,413	27,178	25,396	24,678
Total Liabilities	30,034	30,747	27,685	28,255	21,241	17,037	15,252	17,336	14,711	14,332
Total Current Liabilities	16,939	18,872	17,178	15,331	13,394	10,929	10,077	9,406	7,822	8,152
Short-Term Debt	577	1,443	2,092	1,953	600	699	1,694	291	512	600
Accounts Payable	5,259	6,569	5,238	4,509	4,013	3,754	3,067	4,069	2,467	2,212
Current Deferred Revenue	260	266	286	254	318	247	283	378	280	364
Other Current Liabilities	10,843	10,594	9,562	8,615	8,463	6,229	5,033	4,668	4,563	4,976
Total Noncurrent Liabilities	13,095	11,875	10,507	12,924	7,847	6,108	5,175	7,930	6,889	6,180
Long-Term Debt	11,144	10,213	9,034	10,541	6,060	4,967	4,375	4,770	3,792	3,794
Other Noncurrent Operating Liabilities	1,951	1,662	1,473	2,383	1,787	1,141	800	3,160	3,097	2,386
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	16,445	16,318	15,370	16,103	13,728	12,037	10,161	9,842	10,685	10,346
Total Preferred & Common Equity	16,375	16,262	15,311	16,080	13,728	12,037	10,161	9,842	10,685	10,346
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	16,375	16,262	15,311	16,080	13,728	12,037	10,161	9,842	10,685	10,346
Common Stock	3,496	3,379	3,279	3,115	2,738	2,853	2,568	2,478	2,595	2,563
Retained Earnings	28,317	27,540	25,492	23,086	20,517	17,483	15,072	13,670	11,454	11,017
Treasury Stock	-14,371	-13,658	-12,156	-10,163	-9,918	-8,455	-7,320	-6,325	-3,298	-3,292
Accumulated Other Comprehensive Income / (Loss)	-1,067	-999	-1,304	42	391	156	-159	19	-66	58
Noncontrolling Interest	70	56	59	23	0.00	-	-	-	-	-

This table presents Humana's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Total Assets	50,930	46,479	50,007	50,093	50,091	47,065	55,905	56,455	54,776	43,055	50,765
Total Current Assets	34,422	29,815	32,926	32,858	32,796	29,986	38,253	38,759	37,532	26,183	33,711
Cash & Equivalents	4,250	2,221	5,116	5,501	5,910	4,694	15,148	16,214	13,735	5,061	13,558
Short-Term Investments	17,888	18,214	19,033	17,424	16,697	16,626	15,145	15,251	14,932	13,881	13,124
Accounts Receivable	4,459	2,704	2,144	4,090	3,925	2,035	1,824	1,429	3,107	1,674	1,609
Other Current Assets	7,825	6,676	6,633	5,843	6,264	6,631	6,136	5,865	5,758	5,567	5,420
Plant, Property, & Equipment, net	2,427	2,532	2,693	2,821	2,979	3,030	3,342	3,309	3,234	3,221	3,218
Total Noncurrent Assets	14,081	14,132	14,388	14,414	14,316	14,049	14,310	14,387	14,010	13,651	13,836
Long-Term Investments	1,069	1,118	1,129	1,124	1,110	1,122	1,132	1,122	1,110	1,129	1,113
Goodwill	9,631	9,631	9,590	9,567	9,563	9,550	9,540	9,539	9,320	9,142	9,096
Other Noncurrent Operating Assets	3,381	3,383	3,669	3,723	3,643	3,377	3,638	3,726	3,580	3,380	3,627
Total Liabilities & Shareholders' Equity	50,930	46,479	50,007	50,093	50,091	47,065	55,905	56,455	54,776	43,055	50,765
Total Liabilities	33,111	30,034	32,383	33,365	33,905	30,747	38,901	39,564	38,142	27,685	34,448
Total Current Liabilities	18,043	16,939	18,727	19,790	19,689	18,872	27,823	28,279	26,942	17,178	25,051
Short-Term Debt	577	577	1,136	1,149	822	1,443	2,245	2,022	1,867	2,092	2,799
Accounts Payable	5,380	5,259	5,915	6,527	6,504	6,569	7,600	8,118	7,431	5,238	6,766
Current Deferred Revenue	265	260	195	313	301	266	7,536	7,378	7,220	286	6,012
Other Current Liabilities	11,821	10,843	11,481	11,801	12,062	10,594	10,442	10,761	10,424	9,562	9,474
Total Noncurrent Liabilities	15,068	13,095	13,656	13,575	14,216	11,875	11,078	11,285	11,200	10,507	9,397
Long-Term Debt	12,729	11,144	11,886	11,746	12,390	10,213	9,483	9,722	9,743	9,034	7,798
Other Noncurrent Operating Liabilities	2,339	1,951	1,770	1,829	1,826	1,662	1,595	1,563	1,457	1,473	1,599
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	0.00	-
Total Equity & Noncontrolling Interests	17,819	16,445	17,624	16,728	16,186	16,318	17,004	16,891	16,634	15,370	16,317
Total Preferred & Common Equity	17,751	16,375	17,565	16,671	16,130	16,262	16,949	16,834	16,577	15,311	16,254
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	17,751	16,375	17,565	16,671	16,130	16,262	16,949	16,834	16,577	15,311	16,254
Common Stock	3,530	3,496	3,504	3,453	3,402	3,379	3,395	3,346	3,295	3,279	3,267
Retained Earnings	29,453	28,317	29,118	28,745	28,173	27,540	28,191	27,468	26,619	25,492	25,606
Treasury Stock	-14,364	-14,371	-14,404	-14,405	-14,359	-13,658	-13,134	-12,754	-12,224	-12,156	-11,152
Accumulated Other Comprehensive Income / (Loss)	-868	-1,067	-653	-1,122	-1,086	-999	-1,503	-1,226	-1,113	-1,304	-1,467
Noncontrolling Interest	68	70	59	57	56	56	55	57	57	59	63

This table displays calculated financial ratios and metrics derived from Humana's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	10.70%	14.54%	11.81%	7.66%	18.90%	14.01%	5.85%	-1.13%	0.17%	11.94%
EBITDA Growth	-30.13%	-0.44%	9.58%	-20.11%	28.69%	51.79%	-40.70%	115.19%	-28.00%	9.00%
EBIT Growth	-38.57%	-2.34%	7.85%	-24.64%	32.04%	62.12%	-46.48%	144.80%	-33.47%	10.80%
NOPAT Growth	-35.55%	1.10%	10.98%	-24.56%	43.50%	-1.00%	-3.19%	276.81%	-44.09%	-1.33%
Net Income Growth	-51.13%	-11.35%	-4.50%	-12.86%	24.38%	60.84%	-31.25%	298.70%	-51.88%	11.25%
EPS Growth	-50.10%	-9.42%	-2.60%	-10.43%	25.92%	65.30%	-27.66%	313.02%	-51.78%	14.67%
Operating Cash Flow Growth	-25.50%	-13.21%	102.79%	-59.89%	6.72%	143.17%	-46.36%	109.25%	123.04%	-46.35%
Free Cash Flow Firm Growth	-77.87%	-48.86%	200.46%	-290.54%	8.58%	376.54%	-124.89%	119.84%	1,109.48%	-123.10%
Invested Capital Growth	19.54%	-13.90%	-42.06%	1,323.62%	-35.51%	-49.73%	266.76%	-209.67%	-57.04%	92.88%
Revenue Q/Q Growth	2.39%	3.93%	1.51%	2.46%	3.72%	3.39%	1.75%	0.58%	-0.88%	1.94%
EBITDA Q/Q Growth	-6.97%	-8.77%	0.61%	11.44%	-15.61%	3.94%	-23.44%	27.20%	-24.66%	6.09%
EBIT Q/Q Growth	-9.61%	-11.06%	0.15%	12.78%	-17.52%	4.40%	-27.56%	30.82%	-29.46%	7.74%
NOPAT Q/Q Growth	-2.16%	-13.80%	1.85%	11.78%	-13.33%	-3.17%	12.38%	30.16%	-42.88%	-5.02%
Net Income Q/Q Growth	-10.54%	-17.37%	-0.18%	9.76%	-18.93%	6.16%	11.31%	31.40%	-44.98%	-3.33%
EPS Q/Q Growth	-12.99%	-17.22%	0.14%	9.36%	-18.93%	6.74%	10.65%	31.95%	-45.00%	-3.32%
Operating Cash Flow Q/Q Growth	181.48%	-33.52%	-52.31%	-14.35%	-3.90%	19.04%	636.54%	-3.29%	-61.63%	19.89%
Free Cash Flow Firm Q/Q Growth	114.27%	-26.38%	-41.56%	-20.68%	-1.86%	35.04%	60.01%	-11.91%	-56.54%	18.54%
Invested Capital Q/Q Growth	23.19%	305.42%	829.28%	19.48%	39.11%	134.11%	256.53%	70.54%	262.02%	-14.62%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	14.52%	16.90%	18.50%	16.69%	20.12%	17.00%	19.38%	19.10%	17.23%	18.46%
EBITDA Margin	2.84%	4.51%	5.18%	5.29%	7.13%	6.59%	4.95%	8.83%	4.06%	5.64%
Operating Margin	2.18%	3.77%	4.09%	3.79%	6.46%	4.92%	5.45%	7.93%	3.20%	4.32%
EBIT Margin	2.02%	3.64%	4.27%	4.43%	6.33%	5.70%	4.01%	7.93%	3.20%	4.82%
Profit (Net Income) Margin	1.03%	2.34%	3.02%	3.53%	4.36%	4.17%	2.96%	4.55%	1.13%	2.35%
Tax Burden Percent	70.54%	73.43%	78.53%	87.48%	73.20%	78.33%	81.58%	60.90%	39.56%	52.49%
Interest Burden Percent	72.28%	87.28%	89.90%	91.14%	94.20%	93.46%	90.44%	94.32%	89.14%	92.89%
Effective Tax Rate	24.00%	24.71%	21.36%	14.46%	28.41%	22.08%	18.95%	39.10%	60.44%	47.51%
Return on Invested Capital (ROIC)	32.07%	50.54%	34.12%	45.38%	359.27%	137.76%	522.34%	0.00%	31.50%	53.04%
ROIC Less NNEP Spread (ROIC-NNEP)	39.18%	55.98%	36.80%	42.69%	360.97%	135.40%	531.05%	0.00%	32.40%	52.47%
Return on Net Nonoperating Assets (RNNOA)	-24.65%	-34.86%	-16.32%	-25.70%	-333.13%	-113.37%	-505.51%	0.00%	-25.66%	-40.28%
Return on Equity (ROE)	7.41%	15.68%	17.81%	19.67%	26.14%	24.39%	16.83%	23.85%	5.84%	12.77%
Cash Return on Invested Capital (CROIC)	14.26%	65.47%	87.39%	-128.37%	402.45%	203.95%	-55.41%	0.00%	111.31%	-10.38%
Operating Return on Assets (OROA)	5.09%	8.60%	9.08%	9.28%	15.25%	13.57%	8.67%	16.21%	6.95%	10.86%
Return on Assets (ROA)	2.60%	5.51%	6.41%	7.40%	10.51%	9.94%	6.40%	9.31%	2.45%	5.29%
Return on Common Equity (ROCE)	7.38%	15.62%	17.76%	19.66%	26.14%	24.39%	16.83%	23.85%	5.84%	12.77%
Return on Equity Simple (ROE_SIMPLE)	7.41%	15.27%	18.30%	18.25%	24.53%	22.49%	16.56%	24.87%	5.75%	12.33%
Net Operating Profit after Tax (NOPAT)	1,947	3,021	2,988	2,693	3,569	2,487	2,512	2,595	689	1,232
NOPAT Margin	1.65%	2.84%	3.22%	3.24%	4.63%	3.83%	4.41%	4.83%	1.27%	2.27%
Net Nonoperating Expense Percent (NNEP)	-7.11%	-5.45%	-2.67%	2.69%	-1.70%	2.36%	-8.71%	-1.43%	-0.90%	0.57%
Return On Investment Capital (ROIC_SIMPLE)	6.91%	10.80%	11.28%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	85.48%	83.10%	81.50%	83.31%	79.88%	83.00%	80.62%	80.90%	82.77%	81.54%
SG&A Expenses to Revenue	11.63%	12.40%	13.64%	12.18%	13.03%	11.38%	13.22%	12.21%	13.19%	13.44%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	12.34%	13.13%	14.41%	12.90%	13.66%	12.08%	13.93%	11.18%	14.03%	14.13%
Earnings before Interest and Taxes (EBIT)	2,381	3,876	3,969	3,680	4,883	3,698	2,281	4,262	1,741	2,617
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	3,349	4,793	4,814	4,393	5,499	4,273	2,815	4,747	2,206	3,064
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.87	3.43	4.16	3.64	3.85	3.90	3.72	3.44	2.69	2.41
Price to Tangible Book Value (P/TBV)	4.53	8.30	10.32	11.73	5.70	5.79	6.03	5.15	3.88	3.52
Price to Revenue (P/Rev)	0.26	0.52	0.69	0.70	0.69	0.72	0.66	0.63	0.53	0.46
Price to Earnings (P/E)	25.31	22.39	22.68	19.94	15.72	17.36	22.43	13.81	46.87	19.52
Dividend Yield	1.40%	0.78%	0.63%	0.62%	0.63%	0.62%	0.73%	0.80%	0.60%	0.68%
Earnings Yield	3.95%	4.47%	4.41%	5.01%	6.36%	5.76%	4.46%	7.24%	2.13%	5.12%
Enterprise Value to Invested Capital (EV/IC)	3.14	8.13	8.52	4.82	51.31	29.93	12.48	0.00	14.77	5.76
Enterprise Value to Revenue (EV/Rev)	0.18	0.42	0.59	0.64	0.52	0.56	0.53	0.42	0.36	0.32
Enterprise Value to EBITDA (EV/EBITDA)	6.21	9.39	11.37	12.18	7.27	8.46	10.65	4.75	8.80	5.75
Enterprise Value to EBIT (EV/EBIT)	8.73	11.61	13.79	14.54	8.19	9.78	13.15	5.29	11.15	6.73
Enterprise Value to NOPAT (EV/NOPAT)	10.68	14.89	18.32	19.87	11.20	14.54	11.94	8.68	28.18	14.31
Enterprise Value to Operating Cash Flow (EV/OCF)	7.01	11.30	11.94	23.65	7.09	6.84	13.80	5.56	10.03	20.30
Enterprise Value to Free Cash Flow (EV/FCFF)	24.00	11.50	7.15	0.00	10.00	9.82	0.00	4.21	7.97	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.71	0.71	0.72	0.78	0.49	0.47	0.60	0.51	0.40	0.42
Long-Term Debt to Equity	0.68	0.63	0.59	0.65	0.44	0.41	0.43	0.48	0.35	0.37
Financial Leverage	-0.63	-0.62	-0.44	-0.60	-0.92	-0.84	-0.95	-1.01	-0.79	-0.77
Leverage Ratio	2.86	2.84	2.78	2.66	2.49	2.45	2.63	2.56	2.38	2.41
Compound Leverage Factor	2.06	2.48	2.50	2.42	2.34	2.29	2.38	2.42	2.12	2.24
Debt to Total Capital	41.61%	41.67%	41.99%	43.69%	32.67%	32.01%	37.39%	33.96%	28.71%	29.81%
Short-Term Debt to Total Capital	2.05%	5.16%	7.90%	6.83%	2.94%	3.95%	10.44%	1.95%	3.42%	4.07%
Long-Term Debt to Total Capital	39.57%	36.51%	34.10%	36.86%	29.72%	28.06%	26.96%	32.01%	25.30%	25.74%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.25%	0.20%	0.22%	0.08%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	58.14%	58.13%	57.79%	56.23%	67.33%	67.99%	62.61%	66.04%	71.29%	70.19%
Debt to EBITDA	3.50	2.43	2.31	2.84	1.21	1.33	2.16	1.07	1.95	1.43
Net Debt to EBITDA	-2.94	-2.25	-1.86	-1.14	-2.35	-2.53	-2.76	-2.38	-4.25	-2.38
Long-Term Debt to EBITDA	3.33	2.13	1.88	2.40	1.10	1.16	1.55	1.00	1.72	1.24
Debt to NOPAT	6.02	3.86	3.72	4.64	1.87	2.28	2.42	1.95	6.25	3.57
Net Debt to NOPAT	-5.05	-3.57	-2.99	-1.86	-3.63	-4.35	-3.09	-4.35	-13.61	-5.92
Long-Term Debt to NOPAT	5.72	3.38	3.02	3.91	1.70	2.00	1.74	1.84	5.51	3.08
Altman Z-Score	4.50	4.72	4.92	4.38	5.34	5.52	5.18	4.72	4.57	4.59
Noncontrolling Interest Sharing Ratio	0.38%	0.36%	0.26%	0.08%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.76	1.59	1.52	1.62	1.77	1.82	1.68	1.85	2.07	1.93
Quick Ratio	1.37	1.24	1.20	1.20	1.37	1.47	1.33	1.54	1.63	1.35
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	866	3,914	7,653	-7,618	3,998	3,682	-1,332	5,350	2,434	-241
Operating Cash Flow to CapEx	522.18%	501.39%	409.55%	171.88%	584.96%	717.93%	355.07%	773.09%	367.36%	166.28%
Free Cash Flow to Firm to Interest Expense	1.31	7.94	19.09	-23.37	14.13	15.22	-6.11	22.11	12.88	-1.30
Operating Cash Flow to Interest Expense	4.49	8.08	11.44	6.94	19.93	21.83	9.97	16.74	10.24	4.67
Operating Cash Flow Less CapEx to Interest Expense	3.63	6.46	8.65	2.90	16.52	18.79	7.16	14.57	7.46	1.86
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	2.52	2.36	2.12	2.09	2.41	2.38	2.16	2.05	2.17	2.25
Accounts Receivable Turnover	49.70	57.36	53.25	56.28	70.33	62.66	60.90	50.39	44.55	49.04
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	42.34	34.03	29.51	30.52	35.67	35.17	34.29	34.81	37.65	41.57
Accounts Payable Turnover	17.02	14.97	15.53	16.24	15.87	15.79	12.86	13.31	19.24	20.56
Days Sales Outstanding (DSO)	7.34	6.36	6.85	6.49	5.19	5.82	5.99	7.24	8.19	7.44
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	21.44	24.38	23.50	22.48	23.00	23.11	28.38	27.42	18.97	17.76
Cash Conversion Cycle (CCC)	-14.10	-18.01	-16.65	-15.99	-17.81	-17.29	-22.39	-20.18	-10.78	-10.31
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	6,613	5,532	6,425	11,090	779	1,208	2,403	-1,441	1,314	3,059
Invested Capital Turnover	19.39	17.79	10.60	14.00	77.66	35.94	118.32	-846.72	24.87	23.38
Increase / (Decrease) in Invested Capital	1,081	-893	-4,665	10,311	-429	-1,195	3,844	-2,755	-1,745	1,473
Enterprise Value (EV)	20,788	45,001	54,749	53,499	39,971	36,154	29,991	22,525	19,409	17,624
Market Capitalization	30,550	55,731	63,635	58,489	52,920	46,983	37,749	33,808	28,780	24,911
Book Value per Share	$135.99	$132.09	$120.94	$125.10	$103.73	$90.90	$74.07	$68.89	$71.66	$69.80
Tangible Book Value per Share	$56.01	$54.52	$48.73	$38.81	$70.13	$61.23	$45.66	$45.93	$49.72	$47.77
Total Capital	28,166	27,974	26,496	28,597	20,388	17,703	16,230	14,903	14,989	14,740
Total Debt	11,721	11,656	11,126	12,494	6,660	5,666	6,069	5,061	4,304	4,394
Total Long-Term Debt	11,144	10,213	9,034	10,541	6,060	4,967	4,375	4,770	3,792	3,794
Net Debt	-9,832	-10,786	-8,945	-5,013	-12,949	-10,829	-7,758	-11,283	-9,371	-7,287
Capital Expenditures (CapEx)	568	794	1,120	1,316	964	736	612	524	527	522
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-6,982	-8,763	-7,845	-5,071	-6,380	-5,368	-3,804	-5,312	-2,592	-1,679
Debt-free Net Working Capital (DFNWC)	13,453	12,557	11,097	11,515	10,847	9,658	8,565	8,287	8,880	8,159
Net Working Capital (NWC)	12,876	11,114	9,005	9,562	10,247	8,959	6,871	7,996	8,368	7,559
Net Nonoperating Expense (NNE)	733	537	186	-241	202	-220	829	147	75	-44
Net Nonoperating Obligations (NNO)	-9,832	-10,786	-8,945	-5,013	-12,949	-10,829	-7,758	-11,283	-9,371	-7,287
Total Depreciation and Amortization (D&A)	968	917	845	713	616	575	534	485	465	447
Debt-free, Cash-free Net Working Capital to Revenue	-5.93%	-8.24%	-8.45%	-6.10%	-8.27%	-8.27%	-6.68%	-9.88%	-4.77%	-3.09%
Debt-free Net Working Capital to Revenue	11.42%	11.80%	11.95%	13.86%	14.06%	14.88%	15.05%	15.41%	16.33%	15.03%
Net Working Capital to Revenue	10.93%	10.45%	9.70%	11.51%	13.28%	13.81%	12.07%	14.87%	15.39%	13.92%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$10.01	$20.09	$22.20	$22.79	$25.47	$20.20	$12.24	$16.94	$4.11	$8.54
Adjusted Weighted Average Basic Shares Outstanding	120.64M	120.65M	124.97M	126.63M	128.86M	132.11M	135.57M	137.68M	149.32M	148.30M
Adjusted Diluted Earnings per Share	$9.98	$20.00	$22.08	$22.67	$25.31	$20.10	$12.16	$16.81	$4.07	$8.44
Adjusted Weighted Average Diluted Shares Outstanding	120.64M	120.65M	124.97M	126.63M	128.86M	132.11M	135.57M	137.68M	149.32M	148.30M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	120.64M	120.65M	124.97M	126.63M	128.86M	132.11M	135.57M	137.68M	149.32M	148.30M
Normalized Net Operating Profit after Tax (NOPAT)	1,947	3,021	2,988	2,693	3,569	2,487	2,512	2,595	1,219	1,232
Normalized NOPAT Margin	1.65%	2.84%	3.22%	3.24%	4.63%	3.83%	4.41%	4.83%	2.24%	2.27%
Pre Tax Income Margin	1.46%	3.18%	3.84%	4.04%	5.96%	5.33%	3.62%	7.48%	2.85%	4.48%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	3.61	7.86	9.90	11.29	17.25	15.28	10.46	17.61	9.21	14.07
NOPAT to Interest Expense	2.95	6.13	7.45	8.26	12.61	10.28	11.53	10.72	3.64	6.62
EBIT Less CapEx to Interest Expense	2.75	6.25	7.10	7.25	13.85	12.24	7.66	15.45	6.42	11.26
NOPAT Less CapEx to Interest Expense	2.09	4.52	4.66	4.22	9.21	7.24	8.72	8.56	0.86	3.82
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	35.50%	17.35%	13.99%	12.07%	9.59%	10.75%	15.75%	8.99%	28.83%	13.48%
Augmented Payout Ratio	102.80%	80.68%	88.79%	14.76%	63.65%	50.28%	80.51%	146.45%	45.77%	43.65%

This table displays calculated financial ratios and metrics derived from Humana's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	8.45%	10.40%	11.26%	10.44%	10.73%	17.93%	15.90%	13.04%	11.56%	6.58%	10.16%
EBITDA Growth	46.01%	-121.26%	-26.54%	-17.35%	-27.25%	-181.50%	-10.29%	12.29%	28.38%	12.89%	-15.33%
EBIT Growth	57.80%	-56.85%	-32.34%	-21.42%	-32.08%	-1,302.70%	-13.37%	13.00%	31.83%	19.35%	-18.85%
NOPAT Growth	64.56%	-56.03%	-40.02%	-21.41%	-30.42%	-380.65%	-14.00%	46.05%	35.45%	103.28%	84.78%
Net Income Growth	68.07%	-26.48%	-42.17%	-29.08%	-40.31%	-2,900.00%	-30.43%	37.16%	33.12%	-38.46%	-22.08%
EPS Growth	68.58%	-35.14%	-40.69%	-26.63%	-38.10%	-5,200.00%	-28.54%	39.78%	35.39%	27.27%	-20.69%
Operating Cash Flow Growth	-21.75%	92.60%	48.40%	-61.81%	-93.67%	-39.15%	-85.19%	231.18%	2,114.24%	-5,240.63%	198.17%
Free Cash Flow Firm Growth	88.76%	-324.99%	-374.27%	-175.09%	-149.48%	-86.33%	-75.65%	486.03%	285.65%	146.28%	238.06%
Invested Capital Growth	39.38%	19.54%	299.33%	241.04%	470.58%	-13.90%	-205.68%	-160.94%	-115.59%	-42.06%	-109.49%
Revenue Q/Q Growth	9.92%	-0.63%	-0.48%	-0.24%	11.90%	0.15%	-1.21%	0.02%	19.18%	-1.58%	-3.65%
EBITDA Q/Q Growth	551.09%	-143.09%	-20.02%	-6.08%	783.57%	-114.31%	-10.01%	-17.33%	665.75%	-84.25%	12.64%
EBIT Q/Q Growth	365.19%	-185.12%	-24.49%	-7.42%	363.60%	-136.72%	-12.30%	-19.98%	4,567.57%	-97.36%	14.39%
NOPAT Q/Q Growth	502.64%	-168.53%	-35.79%	-7.12%	481.79%	-126.34%	-15.86%	-17.77%	1,439.91%	-91.93%	42.88%
Net Income Q/Q Growth	281.84%	-242.29%	-29.20%	-8.25%	236.85%	-165.06%	-13.18%	-22.78%	6,977.78%	-101.51%	71.16%
EPS Q/Q Growth	279.76%	-243.97%	-29.18%	-8.02%	244.10%	-163.19%	-12.40%	-22.39%	12,437.50%	-100.85%	71.35%
Operating Cash Flow Q/Q Growth	162.69%	-128.42%	53.17%	186.76%	105.93%	-669.81%	-60.58%	-52.50%	230.43%	-160.65%	781.44%
Free Cash Flow Firm Q/Q Growth	51.64%	80.54%	13.34%	-37.85%	-1,067.66%	-76.27%	-76.28%	-9.17%	167.28%	-57.72%	476.07%
Invested Capital Q/Q Growth	19.73%	23.19%	-3.70%	-1.88%	2.69%	305.42%	31.86%	-157.80%	-123.86%	829.28%	-113.59%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	17.37%	13.12%	14.55%	15.24%	15.15%	13.91%	17.70%	17.71%	18.26%	17.19%	19.36%
EBITDA Margin	6.43%	-1.57%	3.62%	4.50%	4.78%	-0.78%	5.48%	6.01%	7.27%	1.13%	7.07%
Operating Margin	6.27%	-1.86%	2.48%	3.86%	4.17%	-1.32%	4.56%	5.37%	6.43%	0.55%	5.14%
EBIT Margin	5.76%	-2.39%	2.79%	3.68%	3.96%	-1.68%	4.59%	5.17%	6.46%	0.16%	6.14%
Profit (Net Income) Margin	3.87%	-2.34%	1.63%	2.30%	2.50%	-2.04%	3.14%	3.57%	4.63%	-0.08%	5.23%
Tax Burden Percent	73.45%	79.23%	73.73%	73.86%	72.88%	91.37%	75.59%	75.75%	76.70%	25.35%	91.98%
Interest Burden Percent	91.36%	123.50%	79.39%	84.53%	86.45%	132.81%	90.59%	91.32%	93.46%	-191.89%	92.71%
Effective Tax Rate	24.01%	0.00%	23.81%	24.29%	24.75%	0.00%	23.32%	23.45%	22.24%	0.00%	8.25%
Return on Invested Capital (ROIC)	84.30%	-25.23%	162.24%	403.97%	165.44%	-16.38%	0.00%	320.35%	115.22%	4.10%	102.72%
ROIC Less NNEP Spread (ROIC-NNEP)	87.12%	-22.29%	162.71%	405.14%	166.77%	-13.38%	0.00%	321.31%	116.05%	5.60%	101.75%
Return on Net Nonoperating Assets (RNNOA)	-52.28%	14.03%	-150.14%	-385.59%	-145.69%	8.33%	0.00%	-296.19%	-85.94%	-2.49%	-75.51%
Return on Equity (ROE)	32.01%	-11.20%	12.10%	18.38%	19.75%	-8.05%	18.04%	24.16%	29.28%	1.62%	27.21%
Cash Return on Invested Capital (CROIC)	4.59%	14.26%	-113.09%	-128.45%	-81.10%	65.47%	0.00%	0.00%	0.00%	87.39%	0.00%
Operating Return on Assets (OROA)	13.72%	-6.02%	6.06%	7.73%	8.25%	-3.97%	8.80%	9.88%	12.22%	0.35%	11.68%
Return on Assets (ROA)	9.21%	-5.89%	3.55%	4.83%	5.20%	-4.82%	6.03%	6.83%	8.76%	-0.17%	9.96%
Return on Common Equity (ROCE)	31.90%	-11.16%	12.06%	18.32%	19.68%	-8.02%	17.98%	24.10%	29.21%	1.61%	27.16%
Return on Equity Simple (ROE_SIMPLE)	9.67%	0.00%	7.73%	10.24%	12.31%	0.00%	17.74%	20.01%	18.76%	0.00%	17.27%
Net Operating Profit after Tax (NOPAT)	1,530	-380	555	864	930	-244	925	1,099	1,337	87	1,075
NOPAT Margin	4.77%	-1.30%	1.89%	2.92%	3.14%	-0.92%	3.50%	4.11%	5.00%	0.39%	4.72%
Net Nonoperating Expense Percent (NNEP)	-2.83%	-2.94%	-0.47%	-1.16%	-1.33%	-3.00%	-0.51%	-0.96%	-0.83%	-1.50%	0.97%
Return On Investment Capital (ROIC_SIMPLE)	4.92%	-1.35%	-	-	-	-0.87%	-	-	-	0.33%	-
Cost of Revenue to Revenue	82.63%	86.88%	85.45%	84.76%	84.85%	86.09%	82.30%	82.29%	81.74%	82.81%	80.64%
SG&A Expenses to Revenue	10.53%	14.26%	11.36%	10.66%	10.27%	14.46%	12.38%	11.63%	11.14%	15.83%	13.43%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	11.10%	14.98%	12.07%	11.37%	10.98%	15.22%	13.14%	12.35%	11.84%	16.64%	14.22%
Earnings before Interest and Taxes (EBIT)	1,851	-698	820	1,086	1,173	-445	1,212	1,382	1,727	37	1,399
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	2,066	-458	1,063	1,329	1,415	-207	1,447	1,608	1,945	254	1,613
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.80	1.87	2.17	2.70	2.64	3.43	3.52	3.29	3.62	4.16	3.72
Price to Tangible Book Value (P/TBV)	3.93	4.53	4.78	6.34	6.48	8.30	8.06	7.59	8.27	10.32	8.46
Price to Revenue (P/Rev)	0.27	0.26	0.33	0.40	0.39	0.52	0.58	0.56	0.63	0.69	0.66
Price to Earnings (P/E)	18.67	25.31	28.06	26.32	21.39	22.39	19.80	16.39	19.27	22.68	21.57
Dividend Yield	1.34%	1.40%	1.12%	0.95%	1.02%	0.78%	0.71%	0.75%	0.68%	0.63%	0.64%
Earnings Yield	5.36%	3.95%	3.56%	3.80%	4.68%	4.47%	5.05%	6.10%	5.19%	4.41%	4.64%
Enterprise Value to Invested Capital (EV/IC)	2.79	3.14	4.83	6.09	5.66	8.13	0.00	0.00	0.00	8.52	0.00
Enterprise Value to Revenue (EV/Rev)	0.18	0.18	0.23	0.30	0.29	0.42	0.39	0.35	0.44	0.59	0.47
Enterprise Value to EBITDA (EV/EBITDA)	5.52	6.21	7.21	8.52	7.54	9.39	7.62	6.38	7.99	11.37	9.07
Enterprise Value to EBIT (EV/EBIT)	7.22	8.73	9.85	11.21	9.67	11.61	9.19	7.61	9.56	13.79	10.95
Enterprise Value to NOPAT (EV/NOPAT)	8.67	10.68	13.03	14.34	12.33	14.89	11.43	9.38	12.55	18.32	14.79
Enterprise Value to Operating Cash Flow (EV/OCF)	7.69	7.01	0.00	0.00	0.00	11.30	6.69	2.62	3.82	11.94	4.51
Enterprise Value to Free Cash Flow (EV/FCFF)	70.83	24.00	0.00	0.00	0.00	11.50	7.53	2.45	2.85	7.15	3.31
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.75	0.71	0.74	0.77	0.82	0.71	0.69	0.70	0.70	0.72	0.65
Long-Term Debt to Equity	0.71	0.68	0.67	0.70	0.77	0.63	0.56	0.58	0.59	0.59	0.48
Financial Leverage	-0.60	-0.63	-0.92	-0.95	-0.87	-0.62	-1.11	-0.92	-0.74	-0.44	-0.74
Leverage Ratio	2.97	2.86	3.06	3.17	3.20	2.84	3.20	3.19	3.16	2.78	2.95
Compound Leverage Factor	2.71	3.53	2.43	2.68	2.76	3.78	2.90	2.91	2.95	-5.33	2.73
Debt to Total Capital	42.75%	41.61%	42.49%	43.53%	44.94%	41.67%	40.82%	41.01%	41.11%	41.99%	39.37%
Short-Term Debt to Total Capital	1.85%	2.05%	3.71%	3.88%	2.80%	5.16%	7.81%	7.06%	6.61%	7.90%	10.40%
Long-Term Debt to Total Capital	40.90%	39.57%	38.78%	39.65%	42.15%	36.51%	33.01%	33.95%	34.50%	34.10%	28.97%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.22%	0.25%	0.19%	0.19%	0.19%	0.20%	0.19%	0.20%	0.20%	0.22%	0.23%
Common Equity to Total Capital	57.03%	58.14%	57.32%	56.28%	54.87%	58.13%	58.99%	58.79%	58.69%	57.79%	60.39%
Debt to EBITDA	3.33	3.50	3.62	3.24	3.10	2.43	2.23	2.17	2.21	2.31	2.21
Net Debt to EBITDA	-2.48	-2.94	-3.40	-2.80	-2.46	-2.25	-3.75	-3.85	-3.46	-1.86	-3.59
Long-Term Debt to EBITDA	3.18	3.33	3.30	2.95	2.91	2.13	1.80	1.79	1.86	1.88	1.63
Debt to NOPAT	5.22	6.02	6.54	5.45	5.07	3.86	3.35	3.19	3.48	3.72	3.61
Net Debt to NOPAT	-3.88	-5.05	-6.16	-4.71	-4.03	-3.57	-5.62	-5.65	-5.44	-2.99	-5.86
Long-Term Debt to NOPAT	4.99	5.72	5.97	4.96	4.75	3.38	2.71	2.64	2.92	3.02	2.66
Altman Z-Score	4.26	4.28	4.22	4.23	4.11	4.42	3.75	3.57	3.71	4.62	3.86
Noncontrolling Interest Sharing Ratio	0.36%	0.38%	0.33%	0.34%	0.34%	0.36%	0.35%	0.24%	0.25%	0.26%	0.19%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.91	1.76	1.76	1.66	1.67	1.59	1.37	1.37	1.39	1.52	1.35
Quick Ratio	1.47	1.37	1.40	1.37	1.35	1.24	1.15	1.16	1.18	1.20	1.13
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-707	-1,461	-7,506	-8,662	-6,284	649	2,737	11,536	12,701	4,752	11,238
Operating Cash Flow to CapEx	348.42%	-342.86%	1,429.23%	1,064.04%	238.98%	-2,520.85%	535.04%	1,203.03%	2,998.65%	-1,864.36%	2,935.07%
Free Cash Flow to Firm to Interest Expense	-4.42	-8.91	-44.42	-51.56	-39.52	4.45	24.01	96.13	112.40	44.00	110.18
Operating Cash Flow to Interest Expense	2.07	-3.22	10.99	7.22	2.66	-48.86	10.98	26.47	59.18	-47.47	82.87
Operating Cash Flow Less CapEx to Interest Expense	1.48	-4.16	10.22	6.54	1.55	-50.80	8.93	24.27	57.20	-50.02	80.05
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	2.38	2.52	2.17	2.10	2.08	2.36	1.92	1.91	1.89	2.12	1.90
Accounts Receivable Turnover	28.69	49.70	57.97	40.60	31.07	57.36	59.63	41.15	30.45	53.25	52.46
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	44.49	42.34	38.11	36.55	35.17	34.03	31.20	30.71	29.78	29.51	29.92
Accounts Payable Turnover	17.18	17.02	14.51	12.93	13.16	14.97	11.72	11.63	11.73	15.53	12.72
Days Sales Outstanding (DSO)	12.72	7.34	6.30	8.99	11.75	6.36	6.12	8.87	11.99	6.85	6.96
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	21.25	21.44	25.15	28.23	27.75	24.38	31.14	31.39	31.13	23.50	28.70
Cash Conversion Cycle (CCC)	-8.52	-14.10	-18.86	-19.24	-16.00	-18.01	-25.02	-22.52	-19.14	-16.65	-21.74
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	7,918	6,613	5,368	5,574	5,681	5,532	-2,693	-3,952	-1,533	6,425	-881
Invested Capital Turnover	17.69	19.39	85.99	138.15	52.67	17.79	-57.28	77.95	23.05	10.60	21.78
Increase / (Decrease) in Invested Capital	2,237	1,081	8,061	9,526	7,214	-893	-1,812	-10,437	-11,364	-4,665	-10,163
Enterprise Value (EV)	22,090	20,788	25,939	33,928	32,132	45,001	40,058	34,594	41,913	54,749	43,409
Market Capitalization	31,923	30,550	38,136	45,025	42,581	55,731	59,700	55,380	60,023	63,635	60,544
Book Value per Share	$147.13	$135.99	$145.89	$138.35	$133.86	$132.09	$136.79	$134.73	$132.64	$120.94	$128.44
Tangible Book Value per Share	$67.31	$56.01	$66.24	$58.95	$54.50	$54.52	$59.80	$58.39	$58.07	$48.73	$56.56
Total Capital	31,125	28,166	30,646	29,623	29,398	27,974	28,732	28,635	28,244	26,496	26,914
Total Debt	13,306	11,721	13,022	12,895	13,212	11,656	11,728	11,744	11,610	11,126	10,597
Total Long-Term Debt	12,729	11,144	11,886	11,746	12,390	10,213	9,483	9,722	9,743	9,034	7,798
Net Debt	-9,901	-9,832	-12,256	-11,154	-10,505	-10,786	-19,697	-20,843	-18,167	-8,945	-17,198
Capital Expenditures (CapEx)	95	154	130	114	177	283	234	264	223	275	288
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-5,182	-6,982	-8,814	-8,708	-8,678	-8,763	-17,618	-18,963	-16,210	-7,845	-15,223
Debt-free Net Working Capital (DFNWC)	16,956	13,453	15,335	14,217	13,929	12,557	12,675	12,502	12,457	11,097	11,459
Net Working Capital (NWC)	16,379	12,876	14,199	13,068	13,107	11,114	10,430	10,480	10,590	9,005	8,660
Net Nonoperating Expense (NNE)	288	303	75	186	191	296	95	143	99	105	-118
Net Nonoperating Obligations (NNO)	-9,901	-9,832	-12,256	-11,154	-10,505	-10,786	-19,697	-20,843	-18,167	-8,945	-17,198
Total Depreciation and Amortization (D&A)	215	240	243	243	242	238	235	226	218	217	214
Debt-free, Cash-free Net Working Capital to Revenue	-4.31%	-5.93%	-7.66%	-7.77%	-7.94%	-8.24%	-17.21%	-19.21%	-16.95%	-8.45%	-16.64%
Debt-free Net Working Capital to Revenue	14.10%	11.42%	13.33%	12.69%	12.75%	11.80%	12.38%	12.66%	13.02%	11.95%	12.53%
Net Working Capital to Revenue	13.62%	10.93%	12.35%	11.66%	12.00%	10.45%	10.19%	10.62%	11.07%	9.70%	9.47%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$10.31	($5.74)	$3.99	$5.63	$6.13	($4.26)	$6.74	$7.70	$9.91	($0.07)	$9.45
Adjusted Weighted Average Basic Shares Outstanding	120.69M	120.64M	120.41M	120.40M	120.50M	120.65M	123.11M	123.91M	124.94M	124.97M	126.60M
Adjusted Diluted Earnings per Share	$10.30	($5.73)	$3.98	$5.62	$6.11	($4.24)	$6.71	$7.66	$9.87	($0.08)	$9.39
Adjusted Weighted Average Diluted Shares Outstanding	120.69M	120.64M	120.41M	120.40M	120.50M	120.65M	123.11M	123.91M	124.94M	124.97M	126.60M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	120.69M	120.64M	120.41M	120.40M	120.50M	120.65M	123.11M	123.91M	124.94M	124.97M	126.60M
Normalized Net Operating Profit after Tax (NOPAT)	1,530	-380	555	864	930	-244	925	1,099	1,337	87	1,075
Normalized NOPAT Margin	4.77%	-1.30%	1.89%	2.92%	3.14%	-0.92%	3.50%	4.11%	5.00%	0.39%	4.72%
Pre Tax Income Margin	5.27%	-2.95%	2.21%	3.11%	3.42%	-2.23%	4.16%	4.72%	6.04%	-0.32%	5.69%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	11.57	-4.26	4.85	6.46	7.38	-3.05	10.63	11.52	15.28	0.34	13.72
NOPAT to Interest Expense	9.57	-2.32	3.28	5.14	5.85	-1.67	8.11	9.16	11.83	0.80	10.54
EBIT Less CapEx to Interest Expense	10.98	-5.20	4.08	5.79	6.26	-4.99	8.58	9.32	13.31	-2.20	10.89
NOPAT Less CapEx to Interest Expense	8.97	-3.26	2.51	4.46	4.74	-3.61	6.06	6.96	9.86	-1.74	7.72
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	25.04%	35.50%	31.98%	25.54%	22.17%	17.35%	14.01%	12.23%	12.89%	13.99%	13.61%
Augmented Payout Ratio	31.39%	102.80%	130.66%	126.07%	132.80%	80.68%	82.73%	62.42%	50.39%	88.79%	51.91%

Frequently Asked Questions About Humana's Financials

When does Humana's fiscal year end?

According to the most recent income statement we have on file, Humana's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Humana's net income changed over the last 9 years?

Humana's net income appears to be on an upward trend, with a most recent value of $1.21 billion in 2024, falling from $1.28 billion in 2015. The previous period was $2.48 billion in 2023. See Humana's forecast for analyst expectations on what’s next for the company.

What is Humana's operating income?

Humana's total operating income in 2024 was $2.56 billion, based on the following breakdown:

Total Gross Profit: $17.10 billion
Total Operating Expenses: $14.54 billion

How has Humana revenue changed over the last 9 years?

Over the last 9 years, Humana's total revenue changed from $54.29 billion in 2015 to $117.76 billion in 2024, a change of 116.9%.

How much debt does Humana have?

Humana's total liabilities were at $30.03 billion at the end of 2024, a 2.3% decrease from 2023, and a 109.6% increase since 2015.

How much cash does Humana have?

In the past 9 years, Humana's cash and equivalents has ranged from $2.22 billion in 2024 to $5.06 billion in 2022, and is currently $2.22 billion as of their latest financial filing in 2024.

How has Humana's book value per share changed over the last 9 years?

Over the last 9 years, Humana's book value per share changed from 69.80 in 2015 to 135.99 in 2024, a change of 94.8%.

Related Companies

This page (NYSE:HUM) was last updated on 5/28/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Humana (HUM) Financials

Frequently Asked Questions About Humana's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Humana (HUM) Financials

Annual Income Statements for Humana

Quarterly Income Statements for Humana

Annual Cash Flow Statements for Humana

Quarterly Cash Flow Statements for Humana

Annual Balance Sheets for Humana

Quarterly Balance Sheets for Humana

Annual Metrics And Ratios for Humana

Quarterly Metrics And Ratios for Humana

Frequently Asked Questions About Humana's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools